share_log

ALLARITY THERAPEUTICS INC | 8-K: Current report

SEC announcement ·  Mar 5 05:13
Summary by Futu AI
Allarity Therapeutics, Inc., a biopharmaceutical company, has reported the termination of employment of its Chief Medical Officer, Marie Foegh, M.D., as disclosed in a Form 8-K filing with the United States Securities and Exchange Commission. The termination was effective as of February 29, 2024. The company, listed on the Nasdaq Stock Market under the trading symbol ALLR, is classified as an emerging growth company. The report was officially signed by an authorized representative of Allarity Therapeutics, Inc. on March 4, 2024.
Allarity Therapeutics, Inc., a biopharmaceutical company, has reported the termination of employment of its Chief Medical Officer, Marie Foegh, M.D., as disclosed in a Form 8-K filing with the United States Securities and Exchange Commission. The termination was effective as of February 29, 2024. The company, listed on the Nasdaq Stock Market under the trading symbol ALLR, is classified as an emerging growth company. The report was officially signed by an authorized representative of Allarity Therapeutics, Inc. on March 4, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.